Analyst firms · Guggenheim · OTLK

Guggenheim OTLK price target and rating history

Outlook Therapeutics Inc. (OTLK) · Health Care

Guggenheim rates Outlook Therapeutics Inc. (OTLK) Neutral with a $5 price target, as of its latest action on Aug 28, 2025. It has published 4 rating actions on OTLK since April 2023, including 1 upgrade and 2 downgrades.

Current rating
Neutral
Price target
$5
Median target, all firms
Too few
Actions on OTLK
4

Every Guggenheim rating on OTLK

How other firms rate OTLK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Piper SandlerOverweight$4Nov 19, 2026
BTIGBuy$4Jul 27, 2026

Questions about Guggenheim and OTLK

What is Guggenheim's price target for OTLK?
Guggenheim's latest stated price target for Outlook Therapeutics Inc. (OTLK) is $5, from its action on Apr 3, 2023.
What is Guggenheim's rating on OTLK?
Guggenheim rates OTLK Neutral, a neutral rating, as of Aug 28, 2025.
When did Guggenheim last change its view on OTLK?
On Aug 28, 2025, Guggenheim downgrades to Neutral from Buy.

More OTLK rating histories

All Guggenheim ratingsOTLK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.